The progress in developing therapies and vaccines for COVID-19 has been extraordinary, and has received extraordinary attention. But there’s another good news story beginning to emerge, about our widening array of defenses against bacterial infectious disease. On the clinical front in the past month, developers have announced positive Phase III trials in difficult diseases that have been marked with prior... Read More
This week’s unveiling of the AMR Action Fund, a $1 billion public/private consortium anchored by 23 pharmaceutical companies to support the development and commercialization of antibiotics, is a welcome development in the fight against antimicrobial resistant infections. The money is important, but it was very encouraging to see the leadership of major pharmaceutical companies — Pfizer, Merck, and Eli... Read More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.